DHR vs MRK: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
MRK trades at a lower forward P/E
(32.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MRK |
| Current Price |
$177.17 |
$113.87 |
| Fair Value Estimate |
$192.90 |
$100.14 |
| Upside to Fair Value |
+8.9%
|
-12.1%
|
| Market Cap |
$125.4B |
$281.2B |
| Forward P/E |
34.1x
|
32.0x
|
| EV / EBITDA |
20.8x
|
17.3x
|
| Price / Sales |
5.1x
|
4.3x
|
| Price / FCF |
23.7x
|
19.9x
|
| Revenue Growth YoY |
+3.7%
|
+4.3%
|
| Gross Margin |
60.7%
|
75.9%
|
| Operating Margin |
21.0%
|
27.6%
|
| Return on Equity |
7.1%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
5.02%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
DHR |
MRK |
| Zone Low |
$144.68 |
$75.11 |
| Zone High |
$163.97 |
$85.12 |
| In Buy Zone? |
No
|
No
|